Literature DB >> 9311714

Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation.

G S Bauldoff1, D R Nunley, J D Manzetti, J H Dauber, R J Keenan.   

Abstract

BACKGROUND: In patients with cystic fibrosis (CF) who are awaiting lung transplant, prolonged exposure to systemic antibiotics has frequently led to airway colonization with resistant isolates of Pseudomonas. This resistance limits the arsenal of effective antimicrobials available for infections after the initiation of immunosuppression and has been considered a theoretical deterrent to lung transplantation.
METHODS: Twenty CF transplant candidates with "pan-resistant" Pseudomonas received maintenance antibiotic therapy with aerosolized colistin sodium (75 mg b.i.d.), and intravenous antibiotics were eliminated. Ten other CF candidates did not use colistin sodium. Sputum cultures and antibiotic sensitivities were followed every 3-6 weeks.
RESULTS: All 20 candidates (100%) who used aerosolized colistin sodium became colonized with sensitive isolates of Pseudomonas in an average of 45.1+/-20.2 days. In contrast, only 3 of 10 CF transplant candidates (30%) who did not use colistin sodium later became colonized with sensitive isolates. The mean time to spontaneous emergence of sensitive organisms was 144.6+/-48.0 days in candidates who did not use colistin sodium and was significantly longer than in the candidates who used colistin sodium (P=0.007). The occurrence of redeveloping sensitive isolates of Pseudomonas was significantly greater in the candidates who used colistin sodium (P<0.05). Of the candidates who used colistin sodium, six have been transplanted at our institution. In five of these six recipients (83.3%) bacterial cultures taken from the explanted lungs continued to demonstrate sensitive organisms.
CONCLUSION: Aerosolized colistin sodium may be a useful therapy to promote emergence of sensitive microbes in CF candidates with pan-resistant isolates of Pseudomonas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9311714     DOI: 10.1097/00007890-199709150-00015

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Feasibility of aerosolized colistin in the era of escalating drug-resistant Pseudomonas pneumonia: pressing need for validation clinical trials.

Authors:  Amar Safdar
Journal:  Intensive Care Med       Date:  2010-04-16       Impact factor: 17.440

Review 2.  New and emerging therapies for pulmonary complications of cystic fibrosis.

Authors:  M R Tonelli; M L Aitken
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Perioperative antibiotics in thoracic surgery.

Authors:  Stephanie H Chang; Alexander S Krupnick
Journal:  Thorac Surg Clin       Date:  2011-10-20       Impact factor: 1.750

Review 4.  Impact of multidrug-resistant organisms on patients considered for lung transplantation.

Authors:  Shmuel Shoham; Pali D Shah
Journal:  Infect Dis Clin North Am       Date:  2013-04-17       Impact factor: 5.982

Review 5.  Nebulized antibiotics in cystic fibrosis.

Authors:  Isabelle Sermet-Gaudelus; Yann Le Cocguic; Agnés Ferroni; Marlène Clairicia; Joel Barthe; Jan-Pierre Delaunay; Valentine Brousse; Gérard Lenoir
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

6.  Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.

Authors:  Argyris Michalopoulos; Sofia K Kasiakou; Zefi Mastora; Kostas Rellos; Anastasios M Kapaskelis; Matthew E Falagas
Journal:  Crit Care       Date:  2005-01-06       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.